Ignite Creation Date:
2025-12-24 @ 6:26 PM
Ignite Modification Date:
2026-01-02 @ 3:01 AM
Study NCT ID:
NCT07231068
Status:
RECRUITING
Last Update Posted:
2025-11-17
First Post:
2025-09-24
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
Sponsor:
Henan Genuine Biotech Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-10-31
Start Date Type:
ACTUAL
Primary Completion Date:
2027-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2025-09-24
First Submit QC Date:
None
Study First Post Date:
2025-11-17
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-13
Last Update Post Date:
2025-11-17
Last Update Post Date Type:
ESTIMATED